Inflammatory Bowel Diseases Clinical Trial
Official title:
Novel Biomarkers in Diagnosis of Inflammatory Bowel Disease
The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing-
inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis
are the two major clinical forms.The global incidence and prevalence of the inflammatory
bowel diseases has increased over the last 2-4 decades . Despite the great progress in
understanding the pathogenesis of these diseases, their etiology remains unclear .
Considerable effort has been devoted to the development of an accurate ,noninvasive
biomarkers that have increased diagnostic sensitivity and specificity .
Osteoprotegerin is a member of the Tumor Necrosis Factor Receptor superfamily of proteins.
Osteoprotegerin is of particular importance in bone metabolism, inflammation , tumorigenesis,
and other processes where cell differentiation, survival, and death are controlled.
Osteoprotegerin activates inflammation in the gut by stimulating immune cells, cytokines, and
the Necrosis factor-κappaB pathway .
Soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane
protein and as a member of tumor necrosis factor superfamily . Soluble Receptor activator of
nuclear factor kappa-Β ligand has been identified to affect the immune system and a binding
partner of ( Osteoprotegerin ), and controls cell proliferation.The interactions between
Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand, Soluble
Receptor activator of nuclear factor kappa-Β have relevance to inflammatory pathways. Soluble
Receptor activator of nuclear factor kappa-Β ligand- Soluble Receptor activator of nuclear
factor kappa-Β ligand binding activates pathways that contribute to the survival of
T-lymphocytes and dendritic cells .
Status | Not yet recruiting |
Enrollment | 70 |
Est. completion date | January 30, 2024 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Newly diagnosed patients (untreated) by clinical and endoscopic examination and not received treatment . Exclusion Criteria: - patients have autoimmune diseases - patients with cancer |
Country | Name | City | State |
---|---|---|---|
Egypt | Assuit Medical University | Assiut | |
Egypt | Assuit Medical University | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease | measuring level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease then it will measured again after treated with infliximab | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02874365 -
Intestinal Stem Cells Characterization
|
N/A |